PlainPharmaWatch

CMS Open Payments · Program Year 2024

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. reported $123,464,722.93 in payments to 5,932 physicians and teaching hospitals across 36,508 transactions.

See the rankings → How this is sourced
$123.5M
Total payments
36,508
Transactions
5,932
Recipients
−$642.0K
General Payments vs PY2023

Regeneron Pharmaceuticals, Inc. reported $123,464,722.93 in payments to 5,932 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #20 of 1,925 reporting manufacturers (0.9% of all US industry payments), averaging $20.8K per recipient across 9 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Regeneron Pharmaceuticals, Inc. pairs top-1% payment volume with an unusually diversified payment pattern across a wide recipient base.

#20
of 1,925 companies
0.9%
of all US industry payments
0.1%
paid to its single top recipient
9
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Regeneron Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $642.0K (−6.6%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: REGENERON PHARMACEUTICALS, INC.PY2023: REGENERON PHARMACEUTICALS, INC.PY2024: Regeneron Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$9.8MPY2024$9.1M
PY2023
$9,757,861.29
PY2024
$9,115,877.17

How Regeneron Pharmaceuticals, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Regeneron Pharmaceuticals, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$123,464,723 Top 1% higher than 99% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Below this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Below this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). This entry sits in this band. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. ranks #20 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, representing 0.9% of all industry payments reported nationwide for the year. The underlying total is $123,464,722.93 across 36,508 transactions to 5,932 physicians and teaching hospitals - $3.4K per transaction and $20.8K per recipient on average.

The 9-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $6.6M, accounting for 5.3% of the company's reported total and 1,877 transactions.

General Payment Breakdown by Type

"Consulting Fee" leads Regeneron Pharmaceuticals, Inc.'s 9-category general-payment breakdown at $6.6M, 5.3% of the reported total.

How Regeneron Pharmaceuticals, Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$6.6M2. Travel and Lodging$815.0K3. Grant$593.9K4. Royalty or License$536.0K5. Space Rental or Facility …$375.4K6. Food and Beverage$202.1K7. Compensation for Services…$12.5K8. Education$6.9K9. Charitable Contribution$5.2K
Payment Type Amount Transactions
Consulting Fee $6.6M 1,877
Travel and Lodging $815.0K 1,287
Grant $593.9K 59
Royalty or License $536.0K 38
Space Rental or Facility Fees $375.4K 21
Food and Beverage $202.1K 2,612
Compensation for Services Other Than Consulting $12.5K 1
Education $6.9K 11
Charitable Contribution $5.2K 26

Recipient Concentration in General Payments

The five largest recipient relationships account for $3,628,787.33 (39.8%) of $9,115,877.17 in this company's General Payments records across 1,654 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Regeneron Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Huda Zoghbi$881.3KJoseph Leonard Goldstein$829.7KMichael S Brown$825.2KCraig Thompson$707.3KRonald Reagan Ucla$385.4K
  1. 1

    Huda Zoghbi

    $881,253.04 across 56 reported transactions

  2. 2

    Joseph Leonard Goldstein

    $829,671.28 across 64 reported transactions

  3. 3

    Michael S Brown

    $825,173.28 across 69 reported transactions

  4. 4

    Craig Thompson

    $707,320.21 across 40 reported transactions

  5. 5

    Ronald Reagan Ucla

    $385,369.52 across 23 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $3.4K. Average per recipient: $20.8K.

Total Amount

$123,464,722.93

Avg per Transaction

$3.4K

Avg per Recipient

$20.8K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Regeneron Pharmaceuticals, Inc. Share

0.9%

#20 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Regeneron Pharmaceuticals, Inc.

AstraZeneca UK Limited

$124.7M 2,367 recipients

Sanofi US Services Inc.

$114.0M 478 recipients

Edge Endo LLC

$113.4M 40 recipients

Trimed, Inc.

$111.0M 2,318 recipients

Vertex Pharmaceuticals Incorporated

$109.6M 10,996 recipients

Arthrex, Inc.

$109.0M 49,842 recipients

Frequently Asked Questions

How much did Regeneron Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $123,464,722.93 from Regeneron Pharmaceuticals, Inc. to physicians and hospitals across 36,508 transactions - 0.9% of all industry payments reported that year.
How many physicians received payments from Regeneron Pharmaceuticals, Inc.? ▾
5,932 physicians and teaching hospitals received payments from Regeneron Pharmaceuticals, Inc. in 2024, averaging $20.8K per recipient.
What types of payments did Regeneron Pharmaceuticals, Inc. make? ▾
9 categories of general payment make up Regeneron Pharmaceuticals, Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Consulting Fee" at $6.6M, representing 5.3% of the company's reported total.
How does Regeneron Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Regeneron Pharmaceuticals, Inc. ranks #20 by total payment amount.
What is the average payment size from Regeneron Pharmaceuticals, Inc.? ▾
The average transaction from Regeneron Pharmaceuticals, Inc. was $3.4K in 2024. The company made 36,508 total transactions to 5,932 recipients.
Where does the payment data for Regeneron Pharmaceuticals, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Regeneron Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.